X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with FDC LTD. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA FDC LTD. ELDER PHARMA/
FDC LTD.
 
P/E (TTM) x -0.2 23.9 - View Chart
P/BV x 0.1 5.0 2.0% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ELDER PHARMA   FDC LTD.
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
FDC LTD.
Mar-14
ELDER PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs380144 264.8%   
Low Rs18879 238.0%   
Sales per share (Unadj.) Rs491.247.6 1,032.7%  
Earnings per share (Unadj.) Rs-3.27.6 -41.8%  
Cash flow per share (Unadj.) Rs14.49.0 159.9%  
Dividends per share (Unadj.) Rs02.25 0.0%  
Dividend yield (eoy) %02.0 0.0%  
Book value per share (Unadj.) Rs376.547.5 792.1%  
Shares outstanding (eoy) m20.54177.83 11.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.62.3 24.7%   
Avg P/E ratio x-89.314.6 -610.5%  
P/CF ratio (eoy) x19.712.3 159.6%  
Price / Book Value ratio x0.82.3 32.2%  
Dividend payout %029.6 0.0%   
Avg Mkt Cap Rs m5,83319,784 29.5%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1791,221 178.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,0898,459 119.3%  
Other income Rs m257394 65.2%   
Total revenues Rs m10,3468,852 116.9%   
Gross profit Rs m-7922,070 -38.3%  
Depreciation Rs m361249 145.0%   
Interest Rs m2,75631 8,888.4%   
Profit before tax Rs m-3,6532,184 -167.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125606 20.7%   
Profit after tax Rs m-651,353 -4.8%  
Gross profit margin %-7.824.5 -32.1%  
Effective tax rate %-3.427.7 -12.4%   
Net profit margin %-0.616.0 -4.0%  
BALANCE SHEET DATA
Current assets Rs m9,2404,355 212.2%   
Current liabilities Rs m9,9981,792 557.9%   
Net working cap to sales %-7.530.3 -24.8%  
Current ratio x0.92.4 38.0%  
Inventory Days Days4644 104.2%  
Debtors Days Days6025 243.0%  
Net fixed assets Rs m10,1243,025 334.7%   
Share capital Rs m206179 115.2%   
"Free" reserves Rs m5,5828,243 67.7%   
Net worth Rs m7,7348,453 91.5%   
Long term debt Rs m4,88911 45,691.6%   
Total assets Rs m22,88210,557 216.7%  
Interest coverage x-0.371.4 -0.5%   
Debt to equity ratio x0.60 49,942.6%  
Sales to assets ratio x0.40.8 55.0%   
Return on assets %11.813.1 89.7%  
Return on equity %-0.816.0 -5.3%  
Return on capital %22.323.5 94.9%  
Exports to sales %3.013.3 22.8%   
Imports to sales %0.43.3 12.8%   
Exports (fob) Rs m3071,126 27.2%   
Imports (cif) Rs m43283 15.2%   
Fx inflow Rs m3071,146 26.8%   
Fx outflow Rs m125355 35.3%   
Net fx Rs m181791 22.9%   
CASH FLOW
From Operations Rs m11,7541,485 791.6%  
From Investments Rs m-561-620 90.5%  
From Financial Activity Rs m-6,762-753 898.6%  
Net Cashflow Rs m4,432113 3,928.8%  

Share Holding

Indian Promoters % 39.6 68.9 57.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.7 159.6%  
FIIs % 16.8 7.5 224.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 19.0 190.0%  
Shareholders   16,479 23,730 69.4%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   GLENMARK PHARMA  UNICHEM LAB  DR. REDDYS LAB  BIOCON LTD  ALEMBIC LTD  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Infosys & Axis Bank Top Gainers(01:30 pm)

After opening the day in green, the Indian share markets have continued the momentum and are presently trading on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS